Skye CFO Sharp resigns, CEO Dhillon becomes principal financial officer; regains Nasdaq compliance

Skye Bioscience, Inc.

CFO John P. Sharp resigned Sept. 8, 2026; not due to disagreement with auditors or company.
CEO Punit Dhillon appointed principal financial and accounting officer effective Sept. 8, 2026; compensation unchanged.
Master Services Agreement with Lohman & Associates terminated effective Sept. 8, 2026.
Nasdaq confirmed bid price >=$1.00 for 10 consecutive business days (Aug 24-Sep 4, 2026); compliance regained.

item 1.02 item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Punit Dhillon

Principal Financial and Accounting Officer

SKYE · Skye Bioscience, Inc.

Effective: 2026-09-08
Filed: September 11, 2026, 4:13 PM ET

In connection with Mr. Sharp’s departure, on September 9, 2026, the Board of Directors of the Company appointed Punit Dhillon, the Company’s President and Chief Executive Officer, as the Company’s principal financial and accounting officer, effective as of September 8, 2026.

Departed

John P. Sharp

Chief Financial Officer

SKYE · Skye Bioscience, Inc.

Effective: 2026-09-08
Successor: Punit Dhillon
Filed: September 11, 2026, 4:13 PM ET

On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Punit Dhillon was appointed as Principal Financial and Accounting Officer at Skye Bioscience, Inc..

Action: appointed
Role: Principal Financial and Accounting Officer

Exact text from the filing

In connection with Mr. Sharp’s departure, on September 9, 2026, the Board of Directors of the Company appointed Punit Dhillon, the Company’s President and Chief Executive Officer, as the Company’s principal financial and accounting officer, effective as of September 8, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John P. Sharp resigned as Chief Financial Officer at Skye Bioscience, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.

View on SEC.gov

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-061558

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.